Palonosetron Reig Jofre

Palonosetron, the active ingredient in Palonosetron Reig Jofre, is a 5-HT3 receptor antagonist presented as a strength/form for injection use. It is used to prevent nausea and vomiting associated with chemotherapy and postoperative settings in adult patients.

GNH USA supplies Palonosetron Reig Jofre as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Palonosetron is a selective 5‑HT3 receptor antagonist indicated for the following clinical situations: - Chemotherapy‑induced nausea and vomiting (CINV): Reduces the incidence and severity of acute and delayed nausea and vomiting following highly emetogenic chemotherapy. - Post‑operative nausea and vomiting (PONV): Decreases the frequency of nausea and the risk of vomiting after surgery. - Radiotherapy‑induced nausea and vomiting: Helps mitigate nausea and vomiting associated with radiation treatment.

Palonosetron is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache: mild to moderate intensity. - Constipation: occasional bowel movement changes. - Fatigue: feeling of tiredness. - Diarrhoea: loose stools. - Dizziness: transient light‑headedness.

Serious or Rare Side Effects: - QT prolongation: abnormal heart rhythm changes on ECG. - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Serotonin syndrome: rare condition when combined with other serotonergic agents. - Severe hypotension: marked drop in blood pressure. - Cardiac arrhythmias: irregular heartbeats beyond QT changes.

When using Palonosetron, several safety considerations should be observed: - Assess patient history: review the individual medical history for cardiac arrhythmia and electro‑electro c  elect elect etc. - Monitor   "); - Monitor ");. - ");  . - \n-  ewline - \n -  ewline ",